Granahan Investment Management, LLC Cytom X Therapeutics, Inc. Transaction History

Granahan Investment Management, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $1.84 Million - $2.51 Million	-279,218 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$6.47 - $7.9 $325,686 - $397,670	-50,338 Reduced 15.27%	279,218 $1.83 Million
Q3 2020 Nov 12, 2020	SELL	$6.55 - $8.83 $187,107 - $252,237	-28,566 Reduced 7.98%	329,556 $2.19 Million
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $684,122 - $1.35 Million	92,449 Added 34.8%	358,122 $2.98 Million
Q1 2020 May 12, 2020	BUY	$3.61 - $8.6 $403,796 - $961,953	111,855 Added 72.72%	265,673 $2.04 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $2,176 - $3,751	421 Added 0.27%	153,818 $1.28 Million
Q3 2019 Nov 15, 2019	BUY	$7.38 - $12.25 $45,564 - $75,631	6,174 Added 4.19%	153,397 $1.13 Million
Q2 2019 Aug 14, 2019	SELL	$9.35 - $11.41 $85,720 - $104,606	-9,168 Reduced 5.86%	147,223 $1.65 Million
Q1 2019 May 14, 2019	SELL	$9.5 - $19.16 $67,982 - $137,108	-7,156 Reduced 4.38%	156,391 $1.68 Million
Q4 2018 Feb 13, 2019	SELL	$12.69 - $18.61 $44,935 - $65,898	-3,541 Reduced 2.12%	163,547 $2.47 Million
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $82,695 - $121,063	4,584 Added 2.82%	167,088 $3.09 Million
Q2 2018 Aug 15, 2018	SELL	$21.38 - $29.68 $1,881 - $2,611	-88 Reduced 0.05%	162,504 $3.72 Million
Q1 2018 May 14, 2018	BUY	$21.76 - $34.22 $1.55 Million - $2.44 Million	71,448 Added 78.39%	162,592 $4.63 Million
Q4 2017 Feb 12, 2018	BUY	$19.0 - $23.09 $1.73 Million - $2.1 Million	91,144	91,144 $1.92 Million

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $58.7M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.